AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22727547 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake after adjustment for survival and inflammatory status
Number of subjects: 107
Study 22727547 — intervention group
Group type: COMPARATOR
Intervention: Total diet energy density
Number of subjects: 107
Study 22729476 — intervention group
Group type: EXPERIMENTAL
Intervention: Study Coordinator Role
Number of subjects: 28
Study 22729476 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-wide leadership activities
Number of subjects: 28
Study 22729476 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional consistency across sites
Number of subjects: 28
Study 22729476 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant retention and data completion rates
Number of subjects: 28
Study 22730421 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaired tetralogy of Fallot (TOF)
Number of subjects: 483
Study 22730421 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 483
Study 22730482 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity C-reactive protein (hsCRP)
Number of subjects: 326
Study 22730482 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble tumour necrosis factor receptor (sTNFR-1)
Number of subjects: 326
Study 22730482 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo)
Number of subjects: 326
Study 22731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 1 mg (elderly)
Number of subjects: 325
Study 22731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg (elderly)
Number of subjects: 325
Study 22731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 2 mg (nonelderly)
Number of subjects: 325
Study 22731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone 3 mg (nonelderly)
Number of subjects: 325
Study 22731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone (1 mg or 2 mg for elderly; 2 mg or 3 mg for nonelderly)
Number of subjects: 325
Study 22731653 — intervention group
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Number of subjects: 325
Study 22732334 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 (biosimilar epoetin-α) administered intravenously aiming for hemoglobin (Hb) target of 10 - 12 g/dl
Number of subjects: 1500
Study 22732334 — intervention group
Group type: EXPERIMENTAL
Intervention: HX575 (biosimilar epoetin-α)
Number of subjects: 1500
Study 22732895 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miRNAs (specifically the miR-200b/429 cluster)
Number of subjects: 0
Study 22732895 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum miRNAs (miR-200b/429 cluster)
Number of subjects: 0
Study 22733017 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-plasma cell therapy
Number of subjects: 76
Study 22733017 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 76
Study 22733020 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 303
Study 22733020 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography (PET)
Number of subjects: 303
Study 22733020 — intervention group
Group type: COMPARATOR
Intervention: Metastatic bone surveys
Number of subjects: 303
Study 22733373 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg IV 30 min before chemotherapy
Number of subjects: 34
Study 22733887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen-1 MR spectroscopy (1H-MRS)
Number of subjects: 52
Study 22733916 — intervention group
Group type: COMPARATOR
Intervention: Without feedback
Number of subjects: 100
Study 22733916 — intervention group
Group type: EXPERIMENTAL
Intervention: With feedback
Number of subjects: 100
Study 22734012 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 75 mg/m² plus cisplatin 60 mg/m² (day 1), followed by oral capecitabine 1875 mg/m² divided into two doses (days 1-14) every 3 weeks; three cycles preoperatively and three cycles postoperatively
Number of subjects: 51
Study 22734071 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP plus bevacizumab
Number of subjects: 64
Study 22734119 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus acupuncture treatment
Number of subjects: 270
Study 22734119 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 270
Study 22734817 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (defined as Hb <11.0 g/dl in children <5 years or <11.5 g/dl in children 5-12 years)
Number of subjects: 299
Study 22734817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA)
Number of subjects: 299
Study 22734817 — intervention group
Group type: COMPARATOR
Intervention: Routine iron supplementation
Number of subjects: 299
Study 22735035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide administration for an average of 84 ± 5 days
Number of subjects: 18
Study 22735035 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide administration
Number of subjects: 18
Study 22735195 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring of blood glucose (SMBG)
Number of subjects: 0
Study 22735430 — intervention group
Group type: EXPERIMENTAL
Intervention: No radiotherapy (47 patients who achieved complete response after 2 cycles)
Number of subjects: 88
Study 22735430 — intervention group
Group type: COMPARATOR
Intervention: 25.5 Gy-involved-field radiotherapy (41 patients with less than complete response)
Number of subjects: 88
Study 22735430 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (both groups combined)
Number of subjects: 88
Study 22735793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory systolic blood pressure (24-h, daytime, night-time)
Number of subjects: 460
Study 22735793 — intervention group
Group type: COMPARATOR
Intervention: Central systolic blood pressure
Number of subjects: 460
Study 22736422 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 98
Study 22736422 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover from medical management to ESS
Number of subjects: 98
Study 22736422 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 98
Study 22736604 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel cancer cell vaccine for prostate cancer
Number of subjects: 1
Study 22736604 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aciclovir and dexamethasone
Number of subjects: 1
Study 22736604 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem examination
Number of subjects: 1
Study 22736616 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjunctival swabbing for bacterial pathogens
Number of subjects: 148
Study 22738806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy registry system
Number of subjects: 72848
Study 22739225 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant preference study using the modified San Francisco Stop Smoking Internet site
Number of subjects: 7763
Study 22739225 — intervention group
Group type: COMPARATOR
Intervention: Previous randomized controlled trials (RCTs)
Number of subjects: 7763
Study 22739576 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)
Number of subjects: 263
Study 22740718 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc added to existing ART for 24 weeks
Number of subjects: 34
Study 22740718 — intervention group
Group type: COMPARATOR
Intervention: Control (existing ART without maraviroc)
Number of subjects: 34
Study 22742414 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported triggers (mean of 12 triggers)
Number of subjects: 296
Study 22742719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 10-year (<10%)/low lifetime (<39%) predicted risk group
Number of subjects: 2070
Study 22742719 — intervention group
Group type: EXPERIMENTAL
Intervention: Low 10-year (<10%)/high lifetime (≥39%) predicted risk group
Number of subjects: 2070
Study 22742719 — intervention group
Group type: EXPERIMENTAL
Intervention: High 10-year (≥10%) predicted risk or diagnosed diabetes group
Number of subjects: 2070
Study 22742742 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin 3,000 IU i.v. with additional titration steps of 600 IU and/or continuous infusion if necessary
Number of subjects: 109
Study 22742881 — intervention group
Group type: EXPERIMENTAL
Intervention: IV busulfan (0.8-1.2 mg/kg) administered four times daily for 4 days
Number of subjects: 63
Study 22742881 — intervention group
Group type: COMPARATOR
Intervention: Oral busulfan (1.45-1.55 mg/kg) administered four times daily for 4 days
Number of subjects: 63
Study 22742881 — intervention group
Group type: EXPERIMENTAL
Intervention: IV busulfan
Number of subjects: 63
Study 22742890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline, tocopherol, and clodronate (PENTOCLO)
Number of subjects: 0
Study 22743310 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma phospholipid ALA (highest quartile)
Number of subjects: 2957
Study 22743310 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ALA (highest quartile)
Number of subjects: 2957
Study 22743380 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMI with coronary injury (6 patients, 11.76%)
Number of subjects: 51
Study 22743380 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMI without coronary injury (10 patients, 19.6%)
Number of subjects: 51
Study 22743380 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for PAMIWCI
Number of subjects: 51
Study 22743380 — intervention group
Group type: COMPARATOR
Intervention: No relationship found
Number of subjects: 51
Study 22743380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 51
Study 22743380 — intervention group
Group type: EXPERIMENTAL
Intervention: PAMI incidence
Number of subjects: 51
Study 22744013 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cumulative risk
Number of subjects: 726
Study 22744013 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of promotive factors
Number of subjects: 726
Study 22744195 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-3350 mixed with 1.9 L of Gatorade
Number of subjects: 46
Study 22745608 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial vaginosis (BV)
Number of subjects: 2236
Study 22745608 — intervention group
Group type: COMPARATOR
Intervention: Normal vaginal flora
Number of subjects: 2236
Study 22747613 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan plus hydrochlorothiazide
Number of subjects: 0
Study 22747613 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine plus hydrochlorothiazide
Number of subjects: 0
Study 22747660 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel-based regimens
Number of subjects: 0
Study 22747660 — intervention group
Group type: EXPERIMENTAL
Intervention: sipuleucel-T, cabazitaxel, and abiraterone
Number of subjects: 0
Study 22747660 — intervention group
Group type: EXPERIMENTAL
Intervention: various promising candidates/regimens
Number of subjects: 0
Study 22748805 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) supplementation (3 g/day)
Number of subjects: 30
Study 22749065 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetapir PET imaging
Number of subjects: 59
Study 22750015 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin D(3) supplementation (0 to 4000 IU/d)
Number of subjects: 318
Study 22750015 — intervention group
Group type: COMPARATOR
Intervention: Baseline serum 25 (OH) D
Number of subjects: 318
Study 22750015 — intervention group
Group type: COMPARATOR
Intervention: Change in serum 25 (OH) D over 12 weeks
Number of subjects: 318
Study 22751081 — intervention group
Group type: EXPERIMENTAL
Intervention: Natrelle Style 410 implants
Number of subjects: 941
Study 22751595 — intervention group
Group type: EXPERIMENTAL
Intervention: IA etanercept injections (12.5 mg, 4 injections every 2 weeks)
Number of subjects: 14
Study 22751958 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2994
Study 22752026 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-mediated myocardial glucose disposal assessed with 2-deoxy-2-[(18)F]fluoroglucose PET.
Number of subjects: 24
Study 22752026 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia
Number of subjects: 24
Study 22752222 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal-hinge group
Number of subjects: 657
Study 22752222 — intervention group
Group type: COMPARATOR
Intervention: Vertical-hinge group
Number of subjects: 657
Study 22752464 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast echocardiography
Number of subjects: 110
Study 22752464 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable analysis
Number of subjects: 110
Study 22752550 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-infrared cholangiography (NIRC) using 1 cm³ of indocyanine green injected intravenously prior to laparoscopic cholecystectomy
Number of subjects: 1
Study 22752550 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative cholangiography (IOC)
Number of subjects: 1
Study 22759444 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressors (n = 39) defined as those with serial LAVI change ≥3.5 mL/m(2) and baseline LAVI between 20 and 34 mL/m(2)
Number of subjects: 518
Study 22759444 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in LAVI in 'Progressors'
Number of subjects: 518
Study 22759444 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline clinical associates of LAVI progression
Number of subjects: 518
Study 22760009 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a and ribavirin for up to 48 weeks
Number of subjects: 401
Study 22760567 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (during hyperinsulinemic euglycemic clamp)
Number of subjects: 0
Study 22760567 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term hypercaloric feeding (30% extra calories from fat and fructose)
Number of subjects: 0
Study 22760567 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 22760567 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercaloric feeding
Number of subjects: 0
Study 22760568 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d vitamin D3 supplementation for 1 year
Number of subjects: 47
Study 22761257 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene B4 (LTB4) at 10 ng/ml in OSA patient monocytes
Number of subjects: 120
Study 22761257 — intervention group
Group type: COMPARATOR
Intervention: In vitro exposure of PMNs from controls to intermittent hypoxia (IH)
Number of subjects: 120
Study 22761257 — intervention group
Group type: EXPERIMENTAL
Intervention: PMNs from OSA patients
Number of subjects: 120
Study 22761263 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicon-based quantum dots (QDs)
Number of subjects: 32
Study 22761263 — intervention group
Group type: COMPARATOR
Intervention: Inactive gold-based QD
Number of subjects: 32
Study 22761263 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 32
Study 22761263 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 22761653 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (37.5 mg daily) and IGRT (50 Gy)
Number of subjects: 25
Study 22762314 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg daily, increased to 150 mg as needed for 12 weeks)
Number of subjects: 25
Study 22762417 — intervention group
Group type: EXPERIMENTAL
Intervention: 7F EXOSEAL™ Vascular Closure Device (VCD)
Number of subjects: 60
Study 22762561 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemophilic subjects
Number of subjects: 104
Study 22762561 — intervention group
Group type: COMPARATOR
Intervention: Non-haemophilic subjects
Number of subjects: 104
Study 22762711 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 1195
Study 22762711 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 1195
Study 22763262 — intervention group
Group type: EXPERIMENTAL
Intervention: Strattice (non-cross-linked, porcine, acellular dermal matrix)
Number of subjects: 80
Study 22763609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500 mg/m² intravenously every 21 days until progression or unacceptable toxicity
Number of subjects: 48
Study 22763609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 48
Study 22764211 — intervention group
Group type: EXPERIMENTAL
Intervention: BM-MNC-treated group
Number of subjects: 20
Study 22766223 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) at 100 μg/day for 28 days
Number of subjects: 13
Study 22766247 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted A/H1N1 influenza vaccine, Focetria
Number of subjects: 7943
Study 22766338 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training (ET) for 4 months
Number of subjects: 40
Study 22766338 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 40
Study 22766773 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (500 mg QD, 250 mg BID, 375 mg BID, 500 mg BID, 750 mg BID) in combination with Bevacizumab (5 mg/kg every 2 weeks, 10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks)
Number of subjects: 67
Study 22766773 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzastaurin (750 mg BID) in combination with any tested dose/schedule of Bevacizumab
Number of subjects: 67
Study 22767640 — intervention group
Group type: EXPERIMENTAL
Intervention: B lymphocyte depletion therapy (iv rituximab 1 g on days 1 and 15 after 125 mg iv methylprednisolone)
Number of subjects: 6
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (10 µg) with Alhydrogel
Number of subjects: 47
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (50 µg) with Alhydrogel
Number of subjects: 47
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (10 µg) with Montanide ISA 720
Number of subjects: 47
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (50 µg) with Montanide ISA 720
Number of subjects: 47
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (10 µg) with AS02
Number of subjects: 47
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: AMA1 vaccine (50 µg) with AS02
Number of subjects: 47
Study 22768052 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Inhibition Assay (GIA)
Number of subjects: 47
Study 22769055 — intervention group
Group type: EXPERIMENTAL
Intervention: 600mcg sublingual misoprostol
Number of subjects: 213
Study 22769055 — intervention group
Group type: COMPARATOR
Intervention: 800mcg sublingual misoprostol
Number of subjects: 213
Study 22770643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone on top of standard of care (SOC)
Number of subjects: 0
Study 22770643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone on top of SOC
Number of subjects: 0
Study 22770643 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) alone
Number of subjects: 0
Study 22770644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral linezolid (600 mg q12h)
Number of subjects: 92
Study 22770644 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vancomycin (15 mg/kg q12h)
Number of subjects: 92
Study 22771101 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep small-bowel spiral enteroscopy
Number of subjects: 78
Study 22772084 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD
Number of subjects: 183
Study 22772084 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 183
Study 22772084 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac dysrhythmias
Number of subjects: 183
Study 22772084 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 183
Study 22772403 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic wound biopsies (two 6-mm punch biopsies, one at the wound edge and one in the wound bed)
Number of subjects: 144
Study 22772403 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic wound biopsies
Number of subjects: 144
Study 22773225 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss + Physical Activity
Number of subjects: 0
Study 22773225 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity
Number of subjects: 0
Study 22773225 — intervention group
Group type: COMPARATOR
Intervention: Successful Aging
Number of subjects: 0
Study 22773225 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy mediation
Number of subjects: 0
Study 22773521 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c ≥ 6.5% (48 mmol/mol)
Number of subjects: 8696
Study 22773521 — intervention group
Group type: EXPERIMENTAL
Intervention: Two HbA1c thresholds: HbA1c ≤ 5.8% (rule-in, 40 mmol/mol) and HbA1c ≥ 6.8% (rule-out, 51 mmol/mol)
Number of subjects: 8696
Study 22773521 — intervention group
Group type: EXPERIMENTAL
Intervention: Two cut-point threshold
Number of subjects: 8696
Study 22773521 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score to determine HbA1c testing
Number of subjects: 8696
Study 22773528 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted 8-channel functional electrical stimulation (FES) system for standing
Number of subjects: 0
Study 22775568 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosinophilic subjects (CSS and HES)
Number of subjects: 276
Study 22775568 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 276
Study 22775772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive control intervention (fMRI Stroop task)
Number of subjects: 20
Study 22775772 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 participants)
Number of subjects: 20
Study 22776196 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant factor IX (nonacog alfa)
Number of subjects: 0
Study 22776426 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccination with three HLA-A24-binding peptides (TTK, LY6K, IMP3) administered with IFA weekly
Number of subjects: 60
Study 22776937 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 0
Study 22777035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal homodigital island flap
Number of subjects: 15
Study 22777035 — intervention group
Group type: COMPARATOR
Intervention: Cross-finger flap
Number of subjects: 15